FDAsafety guidance66% confidence
FDA approves isatuximab-irfc for subcutaneous injection for multiple myeloma indications
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Novo Nordisk; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Obesity · GLP-1 Agonist
- Sub-indication
- General
Related signal: FDA Approves Supplemental Application for Wegovy (Semaglutide)